These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36356318)

  • 1. Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
    Krarup AL; Larsen L; Nayeb AB; Grøntved S; Paaske Johnsen S; Esbjørn M; Fallingborg J; Nielsen GL; Allin K; Jess T; Olesen AE
    Scand J Gastroenterol; 2023 May; 58(5):477-482. PubMed ID: 36356318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond diagnosis: investigating hospital referral impact on biological treatment initiation, hospital admission, and surgery patterns in inflammatory bowel disease - a Danish population based study.
    Larsen L; Olesen AE; Nayeb AB; Grøntved S; Krarup AL
    Scand J Gastroenterol; 2024 Jun; 59(6):690-697. PubMed ID: 38567864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
    Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
    Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
    Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
    Rønnow Sand J; Troelsen FS; Horváth-Puhó E; Henderson VW; Sørensen HT; Erichsen R
    Aliment Pharmacol Ther; 2022 Sep; 56(5):831-843. PubMed ID: 35781292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased use of biologics in the era of TNF-α inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based study from 2003-2016.
    Qvist N; Vadstrup K; Alulis S; Borsi A; Munkholm P; Olsen J
    Scand J Gastroenterol; 2021 May; 56(5):537-544. PubMed ID: 33736551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prevalence of Inflammatory Bowel Disease in Greenland.
    Gantzel RH; Vesterdal JD; Haase AM; Petersen AJ; Grønbæk H; Pedersen ML
    Inflamm Bowel Dis; 2023 Dec; 29(12):1879-1885. PubMed ID: 36702537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
    Burisch J; Jess T; Egeberg A
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
    Olén O; Smedby KE; Erichsen R; Pedersen L; Halfvarson J; Hallqvist-Everhov Å; Bryder N; ; Askling J; Ekbom A; Sachs MC; Sørensen HT; Ludvigsson JF
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3132-3142. PubMed ID: 37061104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk in patients with inflammatory bowel disease: a population-based study.
    Bernstein CN; Blanchard JF; Kliewer E; Wajda A
    Cancer; 2001 Feb; 91(4):854-62. PubMed ID: 11241255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Antidepressants on the Disease Course Among Patients With Crohn's Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study.
    Kristensen MS; Kjærulff TM; Ersbøll AK; Green A; Hallas J; Thygesen LC
    Inflamm Bowel Dis; 2019 Apr; 25(5):886-893. PubMed ID: 30551218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996-2018).
    Elmahdi R; Thomsen LT; Iversen AT; Allin KH; Kjaer SK; Jess T
    United European Gastroenterol J; 2022 Apr; 10(3):287-295. PubMed ID: 35297191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q; Ding Z; Fu AZ; Patel AA
    BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
    Anisdahl K; Svatun Lirhus S; Medhus AW; Moum B; Melberg HO; Høivik ML
    Scand J Gastroenterol; 2021 Oct; 56(10):1163-1168. PubMed ID: 34320885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
    Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
    J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.
    Vind I; Riis L; Jess T; Knudsen E; Pedersen N; Elkjaer M; Bak Andersen I; Wewer V; Nørregaard P; Moesgaard F; Bendtsen F; Munkholm P;
    Am J Gastroenterol; 2006 Jun; 101(6):1274-82. PubMed ID: 16771949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.